Neopterin as a potential prognostic and predictive biomarker in metastatic renal cell carcinoma treated with immune checkpoint inhibitors

被引:0
作者
Studentova, Hana [1 ,2 ]
Hola, Katerina [1 ,2 ]
Melichar, Bohuslav [1 ,2 ]
Spisarova, Martina [1 ,2 ]
机构
[1] Univ Hosp, Dept Oncol, Olomouc, Czech Republic
[2] Palacky Univ, Fac Med & Dent, Dept Oncol, Olomouc, Czech Republic
关键词
Immunotherapy; neopterin; predictive biomarkers; prognostic biomarkers; renal cell carcinoma; MALIGNANT-TUMORS; URINARY NEOPTERIN; JAPANESE PATIENTS; EXPRESSION; NIVOLUMAB; PD-L1; CABOZANTINIB; ACTIVATION; TOLERANCE; SURVIVAL;
D O I
10.1080/14737140.2024.2341734
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Immunotherapy represents a significant and essential component of renal carcinoma therapy (RCC), but the selection of an optimal regimen for an individual patient remains unclear. Despite significant improvements in therapeutic options for RCC, predictive biomarkers for immunotherapeutic agents remain elusive. Neopterin is a biomarker of cell-mediated immune response, with concentrations increased in different disorders, including cancer. High neopterin levels herald, in general, a poor prognosis. Areas covered: This review briefly overviews the contemporary clinical data on biomarkers in metastatic RCC therapy, focusing on neopterin. Expert Opinion: Elevated neopterin levels have been observed in tumors of different primary locations. Research indicates that neopterin may serve as a potential biomarker for assessing the inflammatory status associated with certain cancers. However, it is necessary to interpret neopterin levels in the context of a comprehensive clinical evaluation, as elevated neopterin alone is not specific to cancer and can be influenced by other factors, including comorbid conditions. Neopterin has also been identified as a prognostic biomarker. An increasing neopterin level in serum and urine is associated with advanced cancer, but the role as a potential predictor of response to immunotherapy has yet to be established. A reliable biomarker for optimal therapy selection in metastatic RCC is still putative.
引用
收藏
页码:339 / 345
页数:7
相关论文
共 50 条
  • [41] Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer
    Sivapiragasam, Abirami
    Kumar, Prashanth Ashok
    Sokol, Ethan S.
    Albacker, Lee A.
    Killian, Jonathan K.
    Ramkissoon, Shakti H.
    Huang, Richard S. P.
    Severson, Eric A.
    Brown, Charlotte A.
    Danziger, Natalie
    McGregor, Kimberly
    Ross, Jeffrey S.
    CANCER MEDICINE, 2021, 10 (01): : 53 - 61
  • [42] Computed Tomography Texture Analysis for Predicting Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors
    Park, Hyo Jung
    Qin, Lei
    Bakouny, Ziad
    Krajewski, Katherine M.
    Van Allen, Eliezer M.
    Choueiri, Toni K.
    Shinagare, Atul B.
    ONCOLOGIST, 2022, 27 (05) : 389 - 397
  • [43] Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors
    Shah, A. Y.
    Kotecha, R. R.
    Lemke, E. A.
    Chandramohan, A.
    Chaim, J. L.
    Msaouel, P.
    Xiao, L.
    Gao, J.
    Campbell, M. T.
    Zurita, A. J.
    Wang, J.
    Corn, P. G.
    Jonasch, E.
    Motzer, R. J.
    Sharma, P.
    Voss, M. H.
    Tannir, N. M.
    EUROPEAN JOURNAL OF CANCER, 2019, 114 : 67 - 75
  • [44] Complete Response in Metastatic Clear Cell Renal Cell Carcinoma Patients Treated with Immune-Checkpoint Inhibitors: Remission or Healing? How to Improve Patients' Outcomes?
    Thouvenin, Jonathan
    Masson, Claire
    Boudier, Philippe
    Maillet, Denis
    Kuchler-Bopp, Sabine
    Barthelemy, Philippe
    Massfelder, Thierry
    CANCERS, 2023, 15 (03)
  • [45] Characterization of the immune cell profile in metastatic nasopharyngeal carcinoma treated with chemotherapy and immune checkpoint inhibitors
    Kuo, Yung-Chia
    Tai, Tzong-Shyuan
    Yang, Huang-Yu
    Lui, Kar-Wai
    Chao, Yin-Kai
    Lee, Li-Yu
    Huang, Yenlin
    Fan, Hsien-Chi
    Lin, An-Chi
    Hsieh, Chia-Hsun
    Yang, Zhangung
    Chang, Kai-Ping
    Lin, Chien-Yu
    Wang, Hung-Ming
    Hsu, Cheng-Lung
    AMERICAN JOURNAL OF CANCER RESEARCH, 2024, 14 (12):
  • [46] Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors
    Brown, Jacqueline T.
    Liu, Yuan
    Shabto, Julie M.
    Martini, Dylan J.
    Ravindranathan, Deepak
    Hitron, Emilie Elise
    Russler, Greta Anne
    Caulfield, Sarah
    Yantorni, Lauren Beth
    Joshi, Shreyas S.
    Kissick, Haydn
    Ogan, Kenneth
    Harris, Wayne B.
    Carthon, Bradley C.
    Kucuk, Omer
    Master, Viraj A.
    Bilen, Mehmet Asim
    ONCOLOGIST, 2021, 26 (05) : 397 - 405
  • [47] A Contemporary Review of Immune Checkpoint Inhibitors in Advanced Clear Cell Renal Cell Carcinoma
    Yu, Eun-mi
    Linville, Laura
    Rosenthal, Matthew
    Aragon-Ching, Jeanny B.
    VACCINES, 2021, 9 (08)
  • [48] Impact of sex on prognosis in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitors
    Nemoto, Yuki
    Ishihara, Hiroki
    Nakamura, Kazutaka
    Tachibana, Hidekazu
    Fukuda, Hironori
    Yoshida, Kazuhiko
    Kobayashi, Hirohito
    Iizuka, Junpei
    Shimmura, Hiroaki
    Hashimoto, Yasunobu
    Kondo, Tsunenori
    Takagi, Toshio
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 53 (07) : 611 - 618
  • [49] Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
    Martini, Dylan J.
    Goyal, Subir
    Liu, Yuan
    Evans, Sean T.
    Olsen, T. Anders
    Case, Katherine
    Magod, Benjamin L.
    Brown, Jacqueline T.
    Yantorni, Lauren
    Russler, Greta Anne
    Caulfield, Sarah
    Goldman, Jamie M.
    Nazha, Bassel
    Harris, Wayne B.
    Kissick, Haydn T.
    Master, Viraj A.
    Kucuk, Omer
    Carthon, Bradley C.
    Bilen, Mehmet Asim
    ONCOLOGIST, 2021, 26 (10) : E1742 - E1750
  • [50] Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
    Paderi, Agnese
    Giorgione, Roberta
    Giommoni, Elisa
    Mela, Marinella Micol
    Rossi, Virginia
    Doni, Laura
    Minervini, Andrea
    Carini, Marco
    Pillozzi, Serena
    Antonuzzo, Lorenzo
    CANCERS, 2021, 13 (04) : 1 - 11